New hope for deadly thyroid cancer? drug combo tested before surgery

NCT ID NCT06902376

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether giving a combination of two drugs (XL092 and cemiplimab) before surgery can help people with a rare and fast-growing thyroid cancer called anaplastic thyroid cancer. The study will enroll 12 participants to see if the treatment is safe and helps surgeons remove the tumor completely. The goal is to better control this difficult-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XL092 (a drug) and cemiplimab (an immunotherapy)
What this could lead to: If successful, this combination could make surgery more effective for a very aggressive thyroid cancer, potentially improving survival.
What could go wrong: This is a very early, small phase 1 trial with only 12 participants. The drugs may cause significant side effects, and it is unknown if they will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer thyroid gland undifferentiated (anaplastic) carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC THYROID CANCER BRAF MUTATION-RELATED TUMORS THYROID CANCER

Contacts and locations

Locations

Dana Farber/Harvard Cancer Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.